Calidi Biotherapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Calidi Biotherapeutics is gedaald met een gemiddeld jaarlijks percentage van -25.1%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.3%. De inkomsten zijn daalde met een gemiddeld percentage van 179.8% per jaar.

Belangrijke informatie

-25.1%

Groei van de winst

-7.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-179.8%
Rendement op eigen vermogen	n/a
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Calidi Biotherapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSEAM:CLDI Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-28	17	11
30 Jun 24	-25	17	12
31 Mar 24	-30	17	13
31 Dec 23	-29	16	13
30 Sep 23	-29	17	11
30 Jun 23	-32	16	10
31 Mar 23	-24	15	8
31 Dec 22	-25	16	7
30 Sep 22	-21	11	6
31 Dec 21	-11	6	4

Kwaliteitswinsten: CLDI is momenteel verliesgevend.

Groeiende winstmarge: CLDI is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CLDI is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 25.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CLDI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CLDI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van CLDI zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Calidi Biotherapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden